SCHEMBL5765632

SCHEMBL5765632

COc1nc(Nc2ccccc2)nc(OC)c1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.47
MAPK9 P45984 1/20 0.47
MAPT P10636 4/20 0.45
GAA P10253 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
KCNH3 Q9ULD8 4/20 0.44
POLB P06746 1/20 0.44
RHOA P61586 1/20 0.44
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 1/20 0.42
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
ILK Q13418 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5765637 0.79 GAA (0.52) MAPTGAAMEN1KMT2AKDM4E
SCHEMBL10168705 0.78 AKR1C3 (0.42) MAPK8MAPK9MAPTGAAMEN1
SCHEMBL10168690 0.77 PDE4B (0.52)
SCHEMBL10168707 0.77 S1PR1 (0.45) MAPK8MAPK9MAPTMEN1KMT2A
SCHEMBL5765616 0.75 POLB (0.49) MAPTGAAKMT2AKDM4EPOLB
SCHEMBL5764704 0.74 POLB (0.45) MAPK8GAAMEN1KMT2AKDM4E
SCHEMBL12095430 0.71 PARP10 (0.47) MAPTKDM4EPOLB
SCHEMBL22646 0.70 POLB (0.54) MEN1KMT2AKDM4EPOLBNPC1
SCHEMBL29442375 0.70 SQOR (0.62) MAPTMEN1KMT2AKDM4EPOLB
SCHEMBL10975566 0.70 ADORA2A (0.58) MAPTGAAMEN1KMT2AKCNH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1334972-B1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) PFIZER (US) 2006-04-19 EP disclosed
US-6833372-B2 A hormone inhibitors of gonadotropin releasing hormone, an antigonadotropins, new drug compound contains a furanyl 2-carboxylic acid -(2,4-dimethoxy-pyrimidin-5-yl)-amide groups PFIZER, INC. 2004-12-21 US disclosed
US-20040053951-A1 Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use PFIZER INC. 2004-03-18 US disclosed
WO-2003068769-A1 NON-PEPTIDE COMPOUNDS AFFECTING THE ACTION OF GONADOTROPIN-RELEASING HORMONE (GNRH) PFIZER INC. (US) 2003-08-21 WO disclosed
EP-1334972-A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH) PFIZER INC. (US) 2003-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053951-A1 Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use GNRHR, LHCGR, FSHR MAPK8 2685/4885MAPK9 2762/4885MAPT 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.